Background: There are limited antiretroviral pharmacoenhancers available for pediatric use. Cobicistat (COBI) is a mechanism-based CYP3A inhibitor devoid of antiretroviral activity approved for adults as a pharmacoenhancer of atazanavir 300 mg or darunavir 800 mg in the European Union and as a pharmacoenhancer in the single tablet regimen elvitegravir/COBI/emtricitabine/tenofovir disoproxil fumarate (ECF/TDF; Stribild™) for treatment of HIV-1 infection in numerous countries. This study evaluated the pharmacokinetics (PK) of COBI administered as a 50 mg pediatric immediate release tablet (test) and as a 20 mg pediatric dispersible tablet (test) vs the 150 mg adult tablet formulation (reference). Methodology: This was a prospective, open-label, randomized, multiple cohort, single dose, crossover study in healthy adult subjects. Cohort 1 (n=32) evaluated the pharmacokinetics (PK) of the pediatric immediate release tablets (3 X 50 mg) vs reference. Cohort 2 (n=30) evaluated the PK of the pediatric dispersible tablet (7.5 X 20 mg; tablet split using standard pill cutter) vs reference. All treatments were administered under fed conditions with 240 mL of water. Intensive PK sampling was conducted over 48 hours post dose and PK parameters were calculated using noncompartmental methods. Bioequivalence (BE) was assessed in both Cohorts using geometric mean ratios (GMR) and associated 90% confidence interval (CI) bounds of 80%-125% (>90% power to conclude BE). Palatability was assessed by questionnaire after each treatment. Safety assessments were performed throughout the study and during follow-up. Results: Study treatments were generally well tolerated and all enrolled subjects completed the study, except one subject whom withdrew consent. All formulations were considered palatable. All adverse events (AE) were Grade 1, with one subject experiencing Grade 2 AE while receiving the pediatric immediate release tablets. Mean (%CV) and the GMR (90%CI) of COBI PK parameters are presented in Table 1. COBI exposure (AUClast, AUCinf, and Cmax) were within the protocol-defined BE bounds for both the pediatric immediate release and dispersible tablet formulations vs the reference (adult) tablet formulation. Conclusions: Pediatric formulations of COBI, administered either as 50 mg immediate release tablets or as 20 mg dispersible tablets, were each bioequivalent to the COBI adult tablet formulation, supporting evaluation of these pediatric formulations in HIV infected children.